Evidence map›Paper›PMID 40916616›Full record

ArticleCancer reports (Hoboken, N.J.)2025

m6A-Mediated Methylation Patterns and Their Association With Obstructive Sleep Apnea in Lung Adenocarcinoma.

Lei Xia, Zhuodong Chai, Xiaoying Wei, Yuan Wei, Daxiong Zeng, Junhong Jiang, Jing Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lei XiaDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Centre of Soochow University, Suzhou, Jiangsu, China.
Zhuodong ChaiDepartment of Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy, Texas A&M University, Texas, USA.
Xiaoying WeiDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Centre of Soochow University, Suzhou, Jiangsu, China.
Yuan WeiDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Centre of Soochow University, Suzhou, Jiangsu, China.
Daxiong ZengDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Centre of Soochow University, Suzhou, Jiangsu, China.
Junhong JiangDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Centre of Soochow University, Suzhou, Jiangsu, China.
Jing LiDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Centre of Soochow University, Suzhou, Jiangsu, China.ORCID 0000-0001-8170-0081

Funding

Jiangsu Province Special Program of Medical Science BE2016672Suzhou Science and Technology Planning Project SKY2021026Suzhou Science and Technology Planning Project SLT201917
6 · The paper itself

Abstract

backgroundEpigenetic regulation significantly affects immune responses in lung adenocarcinoma (LUAD). However, the role of RNA N6-methyladenosine (m6A) modification, especially in obstructive sleep apnea-hypopnea syndrome (OSAHS) within LUAD, is not well understood.

methodsThis study examined m6A modification patterns in 973 LUAD patients using 23 regulatory genes. Unsupervised clustering categorized patients by m6A profiles, quantified by an m6A score. Associations with clinical outcomes, including survival, immune infiltration, tumor microenvironment, OSAHS incidence, and drug sensitivity, were analyzed.

resultsm6A regulator mutations were linked to LUAD, revealing two distinct modification patterns and three gene clusters, all tied to immune phenotypes and clinical outcomes. Higher m6A scores correlated with lower survival, more frequent OSAHS, and increased immune activity. Patients with high m6A scores were more sensitive to PD-L1/PD-1 inhibitors and Phenformin, while those with low scores responded better to Cisplatin, Epothilone B, and Talazoparib.

conclusionAnalyses confirmed m6A modification's role in LUAD progression, immune regulation, and outcomes. The m6A score is a valuable prognostic marker associated with survival, OSAHS incidence, and drug sensitivity. These findings highlight m6A's potential as a therapeutic target and biomarker, particularly for LUAD patients with OSAHS.

Indexed as

Adenocarcinoma of LungAdenosineLung NeoplasmsSleep Apnea, ObstructiveAgedBiomarkers, TumorEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationPrognosisTumor MicroenvironmentAdenosineBiomarkers, TumorN-methyladenosineimmune infiltrationimmunotherapylung adenocarcinomam6Amicroenvironmentmutation burdenOSAHSRNA‐seq

Identifiers

PMID40916616
PMCPMC12415354

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.